MedTrace Logo

Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA

NCT03318887 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2017-10-24

No results posted yet for this study

Summary

Sofosbuvir plus daclatasvir with or without ribavirin is one of the currently recommended treatment option for chronic hepatitis C. The objectives were to identify factors associated with sofosbuvir/daclatasvir plasma concentrations variations and to evaluate their impact on viral kinetics.

Conditions

  • Hepatitis C

Interventions

DRUG

Sofosbuvir/daclatasvir with or without ribavirin

Direct-acting antiviral treatment for hepatitis C virus infection

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Principal Investigators

  • Fabien Zoulim, MD, PhD · Hospices Civils de Lyon

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-01
Primary Completion
2014-09-30
Completion
2015-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03318887 on ClinicalTrials.gov